This generic drug company has seen one positive estimate revision over the past 30 days and its Zacks Consensus Estimate has moved higher over the same time frame, suggesting that more solid trading could be ahead for Akorn. So make sure to keep an eye on this stock going forward to see if this recent move higher can turn into more strength down the road.
Akorn currently has a Zacks Rank #1 (Strong Buy) while its Earnings ESP is 0.00%.
Some stocks in the same industry looking equally good include Mallinckrodt plc (MNK), Celator Pharmaceuticals, Inc. (CPXX) and KaloBios Pharmaceuticals, Inc. (KBIO). While Mallinckrodt holds a Zacks Rank #1 (Strong Buy), Celator Pharmaceuticals and KaloBios Pharmaceuticals carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment